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1ABSTRACT
Treatment outcomes of sunitinib treatment 
in advanced renal cell carcinoma patients : a single cancer center 
experience in Korea
Min Hee Hong
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Sun Young Rha)
Purpose : The retrospective study was performed to assess the efficacy 
and toxicity profiles of sunitinib in Korean patients with metastatic renal 
cell carcinoma (RCC).
Materials and Methods : Between January 2005 and December 2008, 
76 Korean patients with recurrent/metastatic RCC who received sunitinib 
were retrospectively reviewed. The primary end point was 
progression-free survival and the secondary end points were overall 
survival and response rate. We also assessed the toxicities associated 
with sunitinib treatment. 
Results : Of the 76 patients, 68 patients (89.5%) were diagnosed with 
clear cell RCC. The median progression-free survival and overall 
survival were 7.2 and 22.8 months, respectively in overall patients. 
Sixty-two patients (81.6%) received 50mg 4 week and 2 week off 
schedule, and 14 patients (18.4%) received 37.5mg daily on a daily 
continuous schedule. The objective response rate and disease control rate 
were 27.6% and 84.2%, respectively. A dose interruption or reduction in 
dose due to adverse events occurred in 76% of the patients, whereas 12% 
of these patients had discontinued treatment. Other common laboratory 
2abnormalities were increased serum creatinine (75.6%), elevated alanine 
aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and 
increased aspartate aminotransferase (53.3%). Grade 3/4 toxicities 
occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), 
stomatitis (10.5%), and hand-foot syndrome (9.2%).
Conclusion : Our results indicate that sunitinib treatment is effective and 
tolerable for recurrent/metastatic RCC patients in Korea. Further studies 
with prognostic or biochemical factors are needed to clarify the different 
toxicity profiles of this study.
----------------------------------------------------------------------------------------
Key words : renal cell carcinoma, sunitinib, Korea
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I. INTRODUCTION
Renal cell carcinoma (RCC) represents 2~3% of all tumors with an incidence 
which is increasing annually.1 Up to 30% of RCC patients present in an advanced 
state, and approximately 40% of patients who undergo curative surgical resection 
experience recurrence during the follow-up.2,3 Though cytokine treatment with 
interleukin-2 or interferon-alpha has been widely used as a first-line treatment of 
metastatic RCC, it has shown a modest survival benefit and a poor quality of life4. 
Therefore, alternative agents with greater efficacy and less toxicity are needed for 
the systemic treatment of renal cell carcinoma. Remarkable improvement in 
understanding the biology and genetics of RCC has facilitated the novel 
target-based approaches for the treatment of metastatic RCC.
Sunitinib is an orally available, multi-targeted tyrosine kinase inhibitor which 
specifically interferes with platelet-derived growth factor receptor and vascular 
endothelial growth factor receptor.5 These receptor tyrosine kinases are known to 
play important roles in the pathogenesis of RCC.6,7 In phase III trials, this agent 
was shown to significantly improve the median progression-free survival (PFS), 
and yield a higher response rate (RR), and afford a better quality of life over 
interferon-alfa8. However, these studies were performed mainly in Western 
populations. Therefore, further studies about the efficacy and safety profiles are 
needed for involving Asian RCC treated with sunitinib.
4We retrospectively performed this descriptive study to assess the efficacy and 
toxicity profiles of sunitinib to determine whether there is a difference in Korean 
patients with metastatic RCC compared to Western patients.
II. MATERIALS AND METHODS
1. Patients
The medical records of RCC patients with recurrent or metastatic disease who 
had received sunitinib treatment at the Yonsei University Health System (YUHS) 
between January 2005 and December 2008 were retrospectively reviewed. The 
inclusion criteria were as follows; Asian ethnicity, metastatic RCC treated with 
sunitinib, and patients with available medical data for evaluating efficacy and 
toxicity. Clinicopathologic factors such as age, gender, tumor histology, Eastern 
Cooperative Oncology Group performance status (ECOG PS), the number of prior 
treatments, sites of metastasis, laboratory findings, and patient survival were 
collected retrospectively and analyzed. We also assessed the Memorial 
Sloan-Kettering Cancer Center (MSKCC) risk scoring system according to a 
previous study.9
2. Sunitinib treatment
Sunitinib was prescribed as a part of clinical or non-clinical trials with 2 different 
schedules: group 1, 50mg orally once daily for 4 weeks followed by a 2 week rest 
period (50mg 4 weeks on - 2 weeks off schedule); and group 2, 37.5mg daily 
continuous dosing. For the evaluation of the response, Response Evaluation 
Criteria In Solid Tumors (RECIST) was applied.10 Regular physical examinations 
and computed tomography or magnetic resonance imaging were performed for 
treatment outcome every 6~8 weeks. Toxicity was evaluated during the sunitinib 
treatment according to the National Cancer Institute common toxicity criteria 
(version 3.0).
3. Statistical analysis
Survival analysis was calculated using the Kaplan-Meier method with Statistical 
5Package for the Social Sciences (SPSS), version 15.0. PFS was defined from the 
date of the 1st dose of sunitinib to the death of any cause or disease progression. 
Overall survival (OS) was defined from the date of the 1st dose of sunitinib to the 
death of any cause. We also analyzed the 1-year PFS rate and OS rates. Toxicities 
were estimated as simple proportions.
III. RESULTS
1. Patients characteristics
Seventy-six RCC patients were included in the analysis (Table 1). The median 
age was 57.5 years (range 29 ~73 years), and the patients consisted of 63 males 
(82.9%) and 13 females (17.1%). Sixty-eight patients (89.5%) were diagnosed 
with clear cell RCC and the others diagnosed with papillary (n=4), chromophobe 
(n=2), and sarcomatoid type (n=1). The distribution of MSKCC scores of 60 
patients with evaluable data were as follows: favorable for 7 patients (11.6%), 
intermediate for 47 patients (78.3%), and poor for 6 patients (10%). The previous 
treatments were as follows: previous nephrectomy in 72 patients (94.7%), 
conventional chemotherapy in 16 patients (21.1%), cytokine treatment in 42 
patients (55.3%), targeted agent in 7 patients (9.2%), and radiotherapy in 16 
patients (21.1%). The number of patients who underwent nephrectomy as a 
curative aim was 35 (46.1%) and pathologic staging in completely resected 
patients was as follows: stage I for 6 (24.0%), stage II for 8 (32.0%), stage III for 9 
(36.0%), and stage IV for 2 (8.0%) with available pathologic data (25 patients). 
The metastatectomy was performed in 4 patients and it included lung 
segmentectomy, retroperitoneal lymphadenectomy, colon resection and 
splenectomy with distal pancreatectomy. 5 patients were treated with sorafenib 
and two with erlotinib/bevacizumab before sunitinib treatment. Number of disease 
sites was as follows: one for 18 patients (23.7%), 2 for 25 patients (32.9%), and > 
2 for 34 patients (43.4%), respectively. Most prevalent site of metastasis were the 
lung (56 patients [73.7%]) followed by the lymph nodes (36 patients [47.4%]), 
bone (29 patients [38.2%]), and liver (8 patients [10.5%]).
6Table 1. Patient characteristics
Characteristics Number (%)
Total patients 76 (100)
Gender
     Male 63 (82.9)
     Female 13 (17.1)
Median age – year (range) 57.5 (27~73)
Histology1
     Clear cell type 68 (89.5)
     Others 7 (9.2)
     Unknown 1 (1.3)
ECOG performance status
     0 28 (36.8)
     1 40 (52.6)
     2 8 (10.5)
Number of disease sites
     1 18 (23.7)
     2 25 (32.9)
     ≥3 33 (43.4)
MSKCC risk factors2
7Characteristics Number (%)
     0 (favorable) 7 (11.6)
     1,2 (intermediate) 47 (78.3)
     ≥3 (poor) 6 (10)
Site of metastasis
     Lung 56 (73.7)
     Liver 8 (10.5)
     Bone 29 (38.2)
     Lymph nodes 36 (47.4)
Previous treatment
Systemic treatment 45 (59.2)
     Cytotoxic agent 16 (21.1)
     Cytokine 42 (55.3)
     Target agent 7 (9.2)
Nephrectomy 72 (94.7)
Radiotherapy 16 (21.1)
Number of previous systemic treatment
     0 31 (40.8)
     1 32 (42.1)
8Characteristics Number (%)
     2 8 (10.5)
     ≥3 5 (6.5)
Schedule
     50mg 4 weeks on - 2 weeks off 62 (81.6)
     37.5mg daily 14 (18.4)
1  Data of cell type in one patient was missing.
2  Risk factors in Memorial Sloan-Kettering Cancer Center (MSKCC) risk 
scoring system are a low hemoglobin level, an elevated corrected calcium 
level, an elevated serum lactate dehydrogenase level, a poor performance 
status and an interval of less than one year between diagnosis and treatment. 
The MSKCC risk factors could not be calculated in 16 patients due to 
incomplete data. ECOG: Eastern Cooperative Oncology Group.
2. Treatment summary and survival outcome
Two different settings in the treatment schedule existed. The majority of the 
patient (n=62 [81.6%]) received the standard regimen of 50 mg 4 weeks on – 2 
weeks off schedule, and 14 patients (18.4%) received the 37.5mg daily schedule. 
The number of the patients who received sunitinib as a first-line systemic 
treatment was 31 (40.8%). After a median of 16.0 months (range, 0.5 – 40.1 
months) of follow-up, 34 patients (44.7%) remained alive with diseases. The 
median treatment duration was 7.2 months (range, 0.5 – 35.7 months), and 
treatment is ongoing in 10 patients (13.2%). The reasons for treatment 
discontinuation were progressive disease (n=54 [81.8%]), and adverse events 
(n=7 [10.6%]). Other reasons of dose discontinuation included withdrawal of 
consent (4 patients) and loss to follow-up.
The median PFS was 7.2 months (95% confidence interval [CI], 4.7 ~ 9.7 
months, Figure 1), and the median OS was 22.8 months (95% CI, 18.7 ~ 26.9 
9months, Figure 2.). The 1-year PFS rate and 1-year OS rate were 36.8% (95% CI, 
26.1 ~ 48.7%) and 61.8% (95% CI, 50.0 ~ 72.6%), respectively. Of the 76
evaluable patients, objective RR (including complete and partial responses) was 
27.6% (95% CI, 18.0 ~ 39.1%) and the disease control rate (including complete 
response, partial response, and stable disease) was 84.2% (95% CI, 74.0 ~ 
91.6%), as shown in Table 2. In 7 non-clear cell type RCC patients, 1 patient had 
a partial response (10%) and disease control was achieved in 6 patients. The 
median PFS was 7.1 months (95% CI, 4.2 ~ 8.0 months) and the median OS was 
11.0 months (95% CI, 6.2 ~ 17.4 months) in the non-clear cell patients. In 
addition, in the subgroup who had prior targeted agent treatment (7 patients), 6 
patients reached stable disease with 1.5 months (95% CI 0.0 ~ 6.7 months) of the 
median PFS and 12.0 months (95% CI, 1.4~22.5 months) of the median OS. We 
also evaluated the difference between dosing schedule. The response rate was 
25.8% and the disease control rate was 82.3% in the 50 mg 4 weeks on – 2 weeks 
off dosing schedule, as compared with 35.7% and 92.9%, respectively, in the 
37.5 mg daily treatment schedules (Table 2). The median PFS in both the 
standard and other dosing schedules was 7.2 months.
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Figure 1. Progression-free survival in Korean patients with metastatic renal cell 
carcinoma.
11
Figure 2. Overall survival in Korean patients with metastatic renal cell 
carcinoma.
Table 2. Best Tumor Response1
Number (%) Total
(n=76)
50mg 4weeks on
2 weeks off (n=62)
37.5mg
daily(n=14)
Objective response 21 (27.6) 16 (25.8) 5 (35.7)
Complete response 1 (1.3) 1 (1.6) 0 (0)
Partial response 20 (26.3) 15 (24.2) 5 (35.7)
Stable disease 43 (56.6) 35 (56.5) 8 (57.1)
Disease control rate 64 (84.2) 51 (82.3) 13 (92.9)
1 Tumor response was assessed according to the Response Evaluation Criteria in 
Solid Tumors (RECIST). No difference was observed in progression-free 
survival (PFS) of both arms (PFS = 7.2months). 
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3. Toxicity
A total 76% of the patients had a dose interruption or dose reduction due to 
adverse events, whereas only 12% of these patients discontinued treatment due to 
toxicity. Stomatitis and diarrhea were the most commonly reported 
treatment-related adverse events (63.2% and 60.5%, respectively), but the rate of 
severe cases with grade 3 or more was not prevalent (10.5% and 6.6%, 
respectively), as shown in Table 3. Adverse events which were reported with a > 
50% frequency were fatigue (57.9%), anorexia (59.2%) and hand-foot syndrome 
(52.6%). A decrease in the left ventricular ejection fraction of grade 1 was 
reported in only 1 case, and was without clinical significance. Thyroid function 
tests were conducted in 45 patients. Eleven cases (24.4%) of hypothyroidism 
were noted, and 8 (17.8%) patients needed thyroid hormone replacement. In 
addition, there was no case in which patient showed clinical signs of hemolytic 
uremic syndrome or thrombotic thrombocytopenic purpura (11).
The most common laboratory abnormality was thrombocytopenia (77.6%), and 
38.2% of the patients experienced grade 3 or 4 thrombocytopenia, which was no 
clinical significance (such as bleeding; Table 4). Other common laboratory 
abnormalities were increased serum creatinine (75.6%), elevated alanine 
aminotransferase (71%), neutropenia (71.1%), anemia (69.7%), and increased 
aspartate aminotrasferase (53.3%). Grade 3 or 4 hyperamlyasemia was reported in 
13.3% of patients, but no signs of clinical pancreatitis were observed.
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Table 3. Treatment-related adverse events
1These data were available on selected 45 patients.
All grades Grade 3 or 4
Treatment-related adverse events, No.(%)
Stomatitis/mucositis 48 (63.2) 8 (10.5)
Diarrhea 46 (60.5) 5 (6.6)
Anorexia 45 (59.2) 2 (2.6)
Fatigue 44 (57.9) 8 (10.5)
Skin discoloration 41 (53.9) 0 (0)
Hand-foot syndrome 40 (52.6) 7 (9.2)
Rash 34 (44.7) 4 (5.3)
Nausea 32 (42.1) 2 (2.6)
Dyspepsia 27 (35.5) 2 (2.6)
Periorbital edema 27 (35.5) 0 (0)
Facial edema 27 (35.5) 0 (0)
Generalized edema 19 (25.0) 0 (0)
Constipation 17 (22.4) 1 (1.3)
Taste alternation 16 (21.1) 0 (0)
Vomiting 16 (21.1) 1 (1.3)
Dyspnea 15 (19.7) 0 (0)
Epistaxis 13 (17.1) 0 (0)
Hypertension 12 (15.8) 1 (1.3)
Abdominal pain 8 (10.5) 1 (1.3)
Pruritis 8 (10.5) 0 (0)
Alopecia 3 (3.9) 0 (0)
Decrease in left ventricular ejection 
fraction
1 (1.3) 0 (0)
1Hypothyroidism 11 (24.4) 1 (2.2)
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Table 4. Treatment-related laboratory abnormalities
Laboratory abnormalities, No.(%) All grades Grade 3 or 4
Hematologic toxicity (n=76)
Leukopenia 47 (61.8) 14 (18.4)
Anemia 53 (69.7) 18 (23.7)
Thrombocytopenia 59 (77.6) 29 (38.2)
Neutropenia 54 (71.1) 22 (28.9)
Non-hematologic toxicity (n=45)
Increased creatinine 34 (75.6) 15 (33.3)
Increased aspartate aminotransferase 24 (53.3) 3 (6.6)
Increased alanine aminotransferase 43 (71.0) 7 (15.5)
Increased total bilirubin 22 (48.9) 7 (15.5)
Hypophosphatemia 16 (35.6) 2 (4.4)
Hyponatremia 6 (13.3) 6 (13.3)
Hypernatremia 20 (44.4) 8 (17.8)
Hypokalemia 5 (11.1) 0 (0)
Hyperkalemia 8 (17.8) 2 (4.4)
Hypercholesterolemia 6 (13.3) 1 (2.2)
Proteinuria 19 (42.2) 0 (0)
Increased amylase 16 (35.6) 6 (13.3)
Increased lipase 1 (2.2) 0 (0)
IV. DISCUSSION
RCC is one of the malignancies with a dismal prognosis because of the modest 
response to conventional chemotherapeutic agents and cytokine therapy. With the 
elucidation of the molecular pathogenesis of RCC, sunitinib, one of the molecular 
targeted agents was introduced for the treatment of metastatic RCC.8,12 Previous 
studies have confirmed the promising efficacy of sunitinib as a standard first-line 
treatment for metastatic clear cell RCC.8,12 However, these studies were mainly 
performed for patients in Western countries. Only one small study was reported 
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for Asian patients with RCC who were treated with sunitinib,13 thereby the 
potential ethnic difference in the efficacy and toxicity of sunitinib have not been 
established. This retrospective study showed that homogeneous Asian patients 
with metastatic or recurrent RCC who received sunitinib had comparable survival 
outcome with patients in previous randomized studies.
For the treatment outcome, the median PFS and OS were 7.2 and 22.8 months, 
respectively. We also showed a 27.6% objective response rate and an 84.2% 
disease control rate in this analysis. Previous global trials have  demonstrated 8.3 
and 11 months of the median PFS and objective response rate of 34% and 31%.8,12
Even though it is difficult to compare this retrospective study with previous phase 
III randomized trials, we observed that metastatic RCC patients in our study also 
benefitted from sunitinib treatment. Interestingly, in our study, more patients with 
poor prognostic factors were included. In terms of MSKCC risk group, 88.3% of 
patients were in the intermediate or poor groups in this study. In addition, unlike 
the reported randomized studies, > 50% of patients had an ECOG PS 1, and 8 
(10.5%) patients with an ECOG PS 2 were also included. Therefore, considering 
the selection bias of randomized controlled trials which includes relatively better 
performance status, this finding may reflect more reliable results in real clinical 
practice with possible benefit from sunitinib treatment for metastatic RCC 
patients.
In terms of non-hematologic toxicity profiles, stomatitis was the most frequent 
adverse event in our study, which accounted for 63.2% of the cases; however 
grade 3 or 4 stomatitis accounted for 10.5% and was manageable. Meanwhile, 
more stomatitis and hand-foot syndrome were noticed in our study compared to 
the global trials. For hand-foot syndrome, a much higher rate of all grades and 
grade 3/4 toxicities (52.6% of all grades, 9.2% of grade 3 or 4) were noted in 
contrast to the previous trials (15%-20% of all grades; 1%-7% of grade 3 or 4). 
Similarly, Hematologic toxicity, especially for thrombocytopenia, was more 
remarkable in this study. All grades of thrombocytopenia were 77.6%, and it was 
similar with Western data.8,12 However, patients in the present study experienced a 
much higher rate of grade 3 or 4 thrombocytopenia (38.2% in YUHS data versus 
16
8% in the randomized phase III trial, respectively). In addition, thrombocytopenia 
was the most common cause of dose reduction, delay, and discontinuation in our 
study. Other grade 3 or 4 hematologic toxicities such as neutropenia (28.9%), 
anemia (23.7%), and leukopenia (18.4%) were also more frequent than in Western 
analyses. This finding was consistent with Japanese study involving sunitinib 
treatment.13 Whether this toxicity is directly related to host factors such as poor PS, 
or prior numbers of treatments remains uncertain. A disparity in the toxicity 
profiles between Eastern and Western countries has been in colon cancer patients 
who received capecitabine.14-16 Compared to Caucasians, a higher incidence of 
hand-foot syndrome and a lower rate of diarrhea occurred in non-Caucasian 
patients treated with capecitabine, suggesting an ethnic difference between 
Western and Eastern patients. As shown in patients receiving capecitabine 
treatment, this finding may be caused by ethnic differences. Therefore, these 
descriptive results should be interpreted cautiously and further study with a larger 
sample size and pharmacokinetic tests are needed to clarify this finding.
The current single center retrospective analysis had several limitations. The 
patients in this retrospective study consisted of a heterogeneous population. 
Thirteen percent of the patients had non-clear cell RCC, and 9% of all patients had 
already received targeted agents before sunitinib. 
Nevertheless, this study represents one of the few studies in which sunitinib 
treatment was evaluated for efficacy and toxicity in Asian patients with RCC. Our 
results indicated that sunitinib treatment was effective and tolerable in Korean 
patients with metastatic RCC. Further studies with biochemical data would further 
clarify the clinical significance of these findings.
V. CONCLUSION
This study assessed sunitinib treatment for recurrent/metastatic Korean patients 
with RCC in terms of efficacy and toxicity. PFS, OS, and RR in Korean patients 
was compatible to Western patients, although some toxicities in Korean patients 
were more frequent and severe, but were endurable.
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ABSTRACT(IN KOREAN)
진행성 신세포암 환자에서의 수니티닙 치료 결과
: 한국에서의 단일 기관 연구
<지도교수 라선영>
연세대학교 대학원 의학과
홍 민 희
목적 : 본 연구는 전이성 신장암에 사용되는 수니티닙의
한국인에서의 효과 및 독성에 대한 후향적 연구이다. 
방법 : 2005년 1월부터 2008년 12월까지, 연세의료원에서
수니티닙 치료를 받았던 재발성/전이성 신장암 환자를 대상으로, 
무진행 생존율, 전체 생존율, 및 반응율을 조사하였으며, 
수니티닙 치료와 관계된 독성을 평가하였다.
결과  : 연구기간 동안 총 76명의 환자가 수니티닙 치료를
받았다. 이중 68명 (89.5%)이 투명세포형이었으며, 62명
(81.6%)의 환자가 50mg 4주 투약 – 2주 휴약 일정으로, 
14명(18.4%)은 37.5mg을 매일 투약 일정으로 수니티닙을
복용하였다. 무진행 생존율 및 전체 생존율의 중앙값은 각각
7.2개월 및 22.8개월이었다. 76%의 환자에게서 이상사례로
인해서 약물의 중단 또는 약물 용량의 감소가 있었으나, 이중
약제 중단을 한 환자는 12% 였다. 흔한 이상 검사실
소견으로는 크리아티닌 상승(75.6%), 알라닌아미노전이효소의
상승(71.0%), 중성구감소(61.8%), 빈혈 (69.7%)와
아스파트아미노전이효소의 상승(53.3%)였다. 3단계 이상의
독성은 혈소판 감소증(38.2%), 피로(10.5%), 구내염(10.5%)와
수족증후군(9.2%) 였다.
결론 : 한국인에게서 수니티닙 치료가 효과적이었으며
허용할만한 독성을 가지고 있었다.
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